A strength of this study lies in the use of NSCLC cell lines with or without TP53 mutations, with or without a mutation of TK-encoding genes such as EGFR, and with different histological subtypes of the original tumors (Table 1). This evidence concerns the gene TP53 and non-small cell lung carcinoma.